| Literature DB >> 24247067 |
Frank A Post1, Daniel Grint2, Anne Marie Werlinrud3, Alexander Panteleev4, Vieja Riekstina5, Evgeniy A Malashenkov6, Alena Skrahina7, Dan Duiculescu8, Daria Podlekareva3, Igor Karpov9, Vasiliy Bondarenko10, Nelly Chentsova11, Jens Lundgren12, Amanda Mocroft2, Ole Kirk12, Jose M Miro13.
Abstract
Observational data from Eastern Europe on the management and outcome of multi-drug-resistant tuberculosis (MDR TB) in HIV positive populations remain sparse in the English-language literature. We compared clinical characteristics and outcomes of 55 patients who were diagnosed with HIV and MDR TB in Eastern Europe between 2004 and 2006 to 89 patients whose Mycobacterium tuberculosis isolates were susceptible to isoniazid and rifampicin. Patients with HIV and MDR TB were young and predominantly male with high rates of intravenous drug use, imprisonment and hepatitis C co-infection. Eighty-four per cent of patients with MDR TB had no history of previous TB drug exposure suggesting that the majority of MDR TB resulted from transmission of drug-resistant M. tuberculosis. The use of non-standardized tuberculosis treatment was common, and the use of antiretroviral therapy infrequent. Compared to those with susceptible tuberculosis, patients with MDR TB were less likely to achieve cure or complete tuberculosis treatment (21.8% vs. 62.9%, p < 0.0001), and they were more likely to die (65.5% vs. 27.0%, p < 0.0001). Our study documents suboptimal management and poor outcomes in HIV positive patients with MDR TB. Implementation of WHO guidelines, rapid TB diagnostics and TB drug susceptibility testing for all patients remain a priority in this region.Entities:
Keywords: Eastern Europe; HIV; MDR; Resistant; Tuberculosis
Mesh:
Substances:
Year: 2013 PMID: 24247067 DOI: 10.1016/j.jinf.2013.09.034
Source DB: PubMed Journal: J Infect ISSN: 0163-4453 Impact factor: 6.072